LGR5 and metastatic colorectal cancer: BNC101, a human monoclonal antibody against the leucin-rich repeat-containing G-protein coupled receptor 5 (LGR5), was developed by Bionomic Limited and evaluated in a phase I, dose escalation study in patients with metastatic colorectal cancer (NCT02726534) [101].